The drugmaker Ely Lilly ( LLY -4.93%) has had a very successful run over the long run. Shares currently trade around $818 and are up 20,030% over the past 40 years. The stock has also performed well ...

After raising its guidance twice this year, Lilly now expects full-year sales to top out at $46 billion, cutting $600 million from the prior upper end of its outlook. Sales of Zepbound were $1.26 ...

After Eli Lilly raised its guidance in the second quarter, it now actually had to lower its guidance a bit. For the full year of fiscal 2024, Eli Lilly is now expecting revenue to be between $45.4 ...

Below, I'm going to break down Lilly's latest milestone and explain why I see now as a great opportunity to scoop up shares. Back in September, Lilly received FDA approval for its atopic ...

Even a juggernaut like Eli Lilly (NYSE: LLY) can miss the mark sometimes. When it reported its third-quarter earnings on Oct. 30, its share price plunged to the tune of 11% before recovering somewhat, ...